Get the essential updates shaping the future of pharma manufacturing and compliance. Subscribe to Pharmaceutical Technology and never miss an industry breakthrough.

Subscribe

Related Content

Saharsh Davuluri's Midyear Take on the Shifting CDMO Landscape Covers Out-Licensing, Agility, and Investment Surprises

BySaharsh Davuluri

July 22nd 2026

Woman holding multiple GLP-1 injection pens, weight loss and diabetes treatment concept | Image Credit: ©Kateryna -stock.adobe.com

Novo Nordisk Sues Eli Lilly Over Zepbound and Mounjaro Ads, Alleging Omitted GLP-1 Dosing Data

BySusan Haigney

July 21st 2026

A top view of medicine powders, liquids in containers, and various manufactured medicine on the American flag. An America pharmaceuticals concept. | image Credit: ©Ming -stock.adobe.com

The FDA Moves to Modernize Drug Manufacturing Registration

BySusan Haigney

July 10th 2026

PharmTech Weekly Roundup–July 10, 2026

BySusan Haigney

July 10th 2026

Teva Pharmaceutical Industries and Polpharma Biologics Collab on Ocrevus (ocrelizumab)

What the Ocrelizumab Deal Does for the Multiple Sclerosis Biosimilar Pipeline

ByZachary Zubulake

July 9th 2026

Searching for a Viable Business Model

Articles in this issue

Related Content

Saharsh Davuluri's Midyear Take on the Shifting CDMO Landscape Covers Out-Licensing, Agility, and Investment Surprises

Novo Nordisk Sues Eli Lilly Over Zepbound and Mounjaro Ads, Alleging Omitted GLP-1 Dosing Data

The FDA Moves to Modernize Drug Manufacturing Registration

PharmTech Weekly Roundup–July 10, 2026

What the Ocrelizumab Deal Does for the Multiple Sclerosis Biosimilar Pipeline

Trending on Pharmaceutical Technology

Everything to Know about BMS & NVidia’s AI Supercomputer

Brent Wilhelm on Cold Chain Pharmaceuticals Reshaping Shipping Needs

Novo Nordisk Sues Eli Lilly Over Zepbound and Mounjaro Ads, Alleging Omitted GLP-1 Dosing Data

Can AI Fix Pharma's Last-Mile Delivery Blind Spot?

Ask the Expert: Drug Approval Submissions